Parkinsn's Archive Treasures Doctors, students, patients and caregivers find current Parkinson's information such as the Algorithm, Caregivers Handbook, and talks by respected Movement Disorder Specialists.
| Mail converted by MHonArc 2.6.10 |
|
Parkinsn's Email List Message
Posting to the Parkinsn List is a benefit of Subscription
NEWS: Tolcapone Approvable [June 1997]
| Mail converted by MHonArc 2.6.10 |
|
Selected Articles: May 27 - June 23, 1997 Tolcapone (Tasmar, Hoffman-La Roche) has reached approvable status at FDA, which generally precedes final approval by a few weeks. The agent is the first of a new class of agents, COMT inhibitors, used with levodopa for Parkinson's disease. These agents inhibit catechol-O-methyltransferase (COMT), an enzyme in the blood that metabolizes levodopa before it reaches the brain. Clinical studies showed that early-stage, nonfluctuating patients had improved activities of daily living while on tolcapone, while late-stage, fluctuating patients had a 20-30% increase in on-time each day. The most common side effect of tolcapone was dyskinesias, and other adverse effects included diarrhea, nausea, sleep disorders, and anorexia. http://www.pharminfo.com/pubs/pnn/pnn11.html#7a ------------------------------------------------------------------------ ----------janet-paterson---50-9---paterson@xxxxxxxxxxxxxxxxxxxxxxxxxxx
Parkinsn's Archive Treasures Doctors, students, patients and caregivers find current Parkinson's information such as the Algorithm, Caregivers Handbook, and talks by respected Movement Disorder Specialists.
Mail converted by MHonArc
2.6.10